Table 3 Clinicopathological factors of 19 patients with Pan-NET who underwent evaluations of MGMT expression before STZ-based treatment.
Characteristics | Total n = 19 |
|---|---|
Age, years, median (range) | 52 (27–75) |
Sex, male/female | 9/10 |
Genetic syndrome | |
MEN type 1 | 0 |
VHL | 0 |
Tumor factor | |
Tumor size, mean ± SD, mm | 56.0 ± 31.0 |
Ki-67 index, mean ± SD | 14.6 ± 16.2 |
Mitosis, 10 HPF, mean ± SD | 4.4 ± 17.0 |
Chromogranin A positive | 13 |
Synaptophysin positive | 18 |
CD-56 positive | 17 |
Lymph node metastasis | 7 |
Liver metastasis | 17 |
Synchronous | 13 |
Metachronous | 4 |
Functionality, nonfunctioning | 17 |
Tumor grade | |
NET-G2 | 15 |
NET-G3 | 4 |
STZ treatment | |
Month on treatment, median (range) | 8.0 (0.8–31.7) |
STZ treatment line | |
2nd | 6 |
3rd | 6 |
4th or later | 7 |
